Paper Details

  1. Home
  2. Paper Details

Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats.

Author: LuGuocai, RenLijun, YuanBojun, ZhangTianbao, ZhangXiaodong, ZhangXiaofang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigates the potential toxicity of HZ1006, a histone deacetylase inhibitor, in Beagle dogs and Sprague Dawley rats. The NOAEL (No Observed Adverse Effect Level) was determined to be 5 mg/kg for dogs and 60 mg/kg for rats.
Paper Details　
Original Abstract of the Article :
Histone deacetylase inhibitors (HDACIs), such as vorinostat and panobinostat, have been shown to have active effects on many hematologic malignancies, including multiple myeloma and cutaneous T-cell lymphoma. Hydroxamate-based (Hb) HDACIs have very good toxicity profiles and are currently being test...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201331/

データ提供：米国国立医学図書館（NLM）

HZ1006: A New Oasis in the Desert of Cancer Treatment

This research takes us on a scientific expedition through the vast desert of cancer research, exploring the potential of HZ1006, a hydroxamate-based histone deacetylase inhibitor, in treating hematologic malignancies. This journey is like a camel's quest for a life-sustaining oasis, seeking to find a safe and effective treatment for these debilitating diseases. The study aims to determine the toxic effects of HZ1006 and identify a non-toxic dose for clinical use, much like a skilled navigator charts a course through a treacherous desert landscape.

HZ1006: A Promising Oasis in the Desert of Cancer Treatment

The research reveals that HZ1006 shows promise as a potential treatment for hematologic malignancies, with a safe dose identified for clinical use. It's like finding a hidden oasis in the desert, offering hope and relief for those battling these aggressive cancers. This study is a testament to the dedication and perseverance of researchers in their quest to develop effective cancer treatments.

Navigating the Desert of Cancer Treatment: HZ1006 as a Guide

This research provides valuable insights for navigating the complex landscape of cancer treatment, offering hope for the development of a safe and effective treatment for hematologic malignancies. It's like a camel's intuition leading it to a hidden oasis, providing a potential solution to combat these debilitating diseases. The study's findings pave the way for future advancements in cancer research.

Dr.Camel's Conclusion

This research highlights the potential of HZ1006 as a promising treatment option for hematologic malignancies, offering hope for a brighter future in the battle against cancer. It's like discovering a new oasis in the desert, providing much-needed relief and a reason for optimism.

Date :
  1. Date Completed 2017-07-28
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27916918

DOI: Digital Object Identifier

PMC5201331

Related Literature

Article Analysis
・Side Effects of panobinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.